The Protocol Review Committee (PRC) is a multi-disciplinary committee whose mission is to provide scientific review for all clinical protocols involving cancer patients at the University of Iowa Hospitals and Clinics, or UICC resources. This review includes any protocol that: 1) involves patients seen in the John and Marry Pappajohn Clinical Cancer Center or cancer patients from other units in the hospital such as the Bone Marrow Transplantation Unit, Radiation Therapy, the General Clinical Research Center, and the Oncology ward of the Children's Hospital of Iowa or 2) uses UICC resources such as the Core facilities. The role of the PRC is complementary to that of the IRB The PRC is complementary to that of the IRB. The PRC ensures that 1) institutional protocols have adequate scientific rationale to justify the hypothesis, 2) experimental design is rational and includes a clearly stated valid statistical section, a realistic assessment of accrual and appropriate response parameters, 3) the scientific question to be answered is of sufficient interest to justify use of UICC resources, 4) investigators have considered all potential basic science correlates that might be pursued as part of their studies, and 5) studies are prioritized that deal with similar patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-02
Application #
6470080
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Lin, Jie; Adjeroh, Donald A; Jiang, Bing-Hua et al. (2018) K2 and K2*: efficient alignment-free sequence similarity measurement based on Kendall statistics. Bioinformatics 34:1682-1689
Koppenhafer, Stacia L; Goss, Kelli L; Terry, William W et al. (2018) mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. Mol Cancer Ther 17:2676-2688
Lutgendorf, Susan K; Thaker, Premal H; Arevalo, Jesusa M et al. (2018) Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer 124:580-586
Krishnamani, Venkatramanan; Peterson, Tabitha A; Piper, Robert C et al. (2018) Informatic Analysis of Sequence Data from Batch Yeast 2-Hybrid Screens. J Vis Exp :
Al-Qurayshi, Zaid; Khadra, Helmi; Chang, Kristi et al. (2018) Risk and survival of patients with medullary thyroid cancer: National perspective. Oral Oncol 83:59-63
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Chiba, Akiko; Raman, Rachna; Thomas, Alexandra et al. (2018) Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clin Breast Cancer 18:144-149
Vikas, Praveen; Borcherding, Nicholas; Zhang, Weizhou (2018) The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res 10:6823-6833
Alexander, Matthew S; Cullen, Joseph J (2018) Treating pancreatic cancer: more antioxidants more problems? Expert Rev Gastroenterol Hepatol 12:849-851
Neuner, Joan M; Kong, Amanda; Blaes, Ann et al. (2018) The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Res Treat :

Showing the most recent 10 out of 1080 publications